Moderna (NASDAQ:MRNA) Earns Neutral Rating from Analysts at Citigroup

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA) in a research note published on Thursday, MarketBeat reports. The brokerage issued a neutral rating and a $40.00 price objective on the stock.

MRNA has been the subject of a number of other reports. Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 price target (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Evercore ISI set a $50.00 price objective on Moderna in a research report on Friday, February 14th. JPMorgan Chase & Co. set a $45.00 price target on Moderna in a research report on Friday, February 14th. Berenberg Bank raised their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Finally, UBS Group lowered their price target on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $59.60.

Moderna Price Performance

Moderna stock opened at $34.62 on Thursday. Moderna has a one year low of $29.25 and a one year high of $170.47. The business has a fifty day moving average price of $35.94 and a 200-day moving average price of $47.37. The firm has a market capitalization of $13.36 billion, a P/E ratio of -3.73 and a beta of 1.86.

Institutional Trading of Moderna

Several large investors have recently modified their holdings of MRNA. Knuff & Co LLC boosted its position in Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after acquiring an additional 244 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. lifted its holdings in shares of Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after purchasing an additional 297 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Finally, Empowered Funds LLC lifted its holdings in shares of Moderna by 6.6% during the third quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock valued at $347,000 after purchasing an additional 322 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.